Drug-associated inflammatory bowel disease: a real-world pharmacovigilance study using the FAERS and JADER databases - Takeaways - MDSpire

Drug-associated inflammatory bowel disease: a real-world pharmacovigilance study using the FAERS and JADER databases

  • By

  • Yuou Ying

  • Mengyuan Shen

  • Jinhan Chen

  • Tongfei Feng

  • Zejiong Li

  • Zhekai Ying

  • Dongdong Yang

  • Ruyi Ju

  • Jiannong Wu

  • July 7, 2026

  • 0 min

Share

  • 1

    The study analyzed FAERS and JADER databases to identify medications associated with inflammatory bowel disease (IBD).

  • 2

    A total of 52,395 reports of drug-associated IBD were identified in FAERS, with a higher proportion of reports from females aged 18–64 years.

  • 3

    Seventeen drugs met all algorithmic criteria and were classified as positive signals, with anti-TNF-α inhibitors being the most frequently reported.

  • 4

    External validation using JADER confirmed consistent signals for certain anti-TNF-α inhibitors and other drug classes linked to IBD.

  • 5

    The median onset of IBD occurred within one year for most drug-associated cases, indicating an early failure-type onset pattern.

Original Source(s)

Drug-associated inflammatory bowel disease: a real-world pharmacovigilance study using the FAERS and JADER databases

  • by Yuou Ying, Mengyuan Shen, Jinhan Chen, Tongfei Feng, Zejiong Li, Zhekai Ying, Dongdong Yang, Ruyi Ju, Jiannong Wu

  • July 7, 2026

Related Content

Escalating anti-tumour necrosis factor exposure with reductions in surgical resection rates in paediatric inflammatory bowel disease: an 18-year real-world population-based cohort study

Host–microbial co-metabolites: from biogenesis to immunomodulation and implications for health and disease

Shared inflammatory architecture and therapeutic tensions between psoriasis and Crohn’s disease